Free tool
FAERS Monitor: Letybo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761225 or its brand name (Letybo, Letibotulinumtoxina-Wlbg). Reports on generic versions are filed under their own applications.
Reports
293
Serious
30
10% of reports
Hospitalization
20
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- therapy non-responder143
- drug effect less than expected81
- botulism15
- drug ineffective15
- headache11
- off label use10
- product quality issue10
- dysphagia9
- dyspnoea8
- injection site pain8
- chest discomfort7
- eyelid ptosis6
- muscular weakness6
- patient dissatisfaction with treatment6
- product temperature excursion issue6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 6 |
| 2025 | 138 |
| 2026 | 149 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,866 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| botulismSignal | 15 | 1325.8 | 806.0 | 18,218 |
| drug effect less than expectedSignal | 81 | 394.5 | 327.6 | 31,255 |
| therapy non-responderSignal | 143 | 229.1 | 203.7 | 32,216 |
| patient dissatisfaction with treatmentSignal | 6 | 224.2 | 101.4 | 1,116 |
| product temperature excursion issueSignal | 6 | 83.9 | 38.0 | 412 |
| eyelid ptosisSignal | 6 | 42.4 | 19.2 | 203 |
| dysphagiaSignal | 9 | 6.8 | 3.6 | 39 |
| product quality issueSignal | 10 | 5.3 | 2.9 | 31 |
| chest discomfortSignal | 7 | 4.9 | 2.4 | 18 |
| muscular weaknessSignal | 6 | 3.8 | 1.7 | 10 |
| injection site pain | 8 | 1.9 | 0.9 | 2 |
| headache | 11 | 1.3 | 0.7 | 0 |
| dyspnoea | 8 | 1.0 | 0.5 | 0 |
| off label use | 10 | 0.8 | 0.4 | 0 |
| drug ineffective | 15 | 0.8 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.